Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Healthcare · Biological Products, (No Diagnostic Substances)
AI confidence 70% · prior close shown (market closed)
RECURSION PHARMACEUTICALS, INC. shows decelerating business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue -56% YoY in Q1 FY2026.
Watch: Significant revenue decline.
4 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 34d ago
Reported figures for RECURSION PHARMACEUTICALS, INC. — research only, not investment advice.
Updated
What happened recently for RECURSION PHARMACEUTICALS, INC. (RXRX) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
Prior close
$3.16
Market cap
$1.69B
Profitable
No
Revenue $7.67M
Net income
$-131.00M
FY Aug 15, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Healthcare · Biological Products, (No Diagnostic Substances)
Investment Snapshot above is the primary AlphaOS analysis for RECURSION PHARMACEUTICALS, INC. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected companies and research pages from the AlphaOS knowledge graph.
Follow RECURSION PHARMACEUTICALS, INC. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.